Working Diagnosis:
Reactive Lymphadenopathy with History of Recurrent Shoulder Subluxation
Treatment:
Her symptoms improved over the course of weeks with a structured home exercise program.
Outcome:
On follow up office examination and imaging review, no axillary lymphadenopathy was palpable. No side effects to COVID-19 vaccination were reported. Good compliance was reported with home exercise program. Left shoulder strength had improved, and there was no apprehension during range of motion testing.
Author's Comments:
This case illustrates the incidental finding of lymphadenopathy in setting of recent COVID-19 immunization on shoulder MRI. <a href="CaseStudyImages/CS2CS1ShoulderPainRe-991.jpg" title="Case Photo #2" data-lity><b>Case Photo #2</b></a> This has been well recognized in oncology literature, but not frequently reported in MSK literature.
Editor's Comments:
For sports medicine physicians
<br>(who order, perform and review imaging studies), this case is an important reminder of patient history in imaging interpretation. Palpable ipsilateral axillary lymphadenopathy has been reported in 10-15% of patients following Covid-19 vaccination (1). Recommendations have been made to share recent vaccine history with the radiologist, to defer imaging (if possible) for 4-6 weeks following vaccination, and to follow up persistent palpable axillary lymphadenopathy at 6 weeks with axillary ultrasound (1)(2).
References:
1. Lehman CD, D'Alessandro HA, Mendoza DP, Succi MD, Kambadakone A, Lamb LR. Unilateral Lymphadenopathy After COVID-19 Vaccination: A Practical Management Plan for Radiologists Across Specialties. J Am Coll Radiol. 2021 Jun;18(6):843-852. doi: 10.1016/j.jacr.2021.03.001. Epub 2021 Mar 4. PMID: 33713605; PMCID: PMC7931722.
<br>
<br>2. Keshavarz P, Yazdanpanah F, Rafiee F, Mizandari M. Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review. Acad Radiol. 2021 Aug;28(8):1058-1071. doi: 10.1016/j.acra.2021.04.007. Epub 2021 May 1. PMID: 33985872; PMCID: PMC8088218.
Return To The Case Studies List.